Physician profile
Brian I Malte
NPI 1669787784
$14,243.46
in general payments reported to CMS, 2019-2025
43 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $831 · 2021: $606 · 2022: $648 · 2023: $1,502 · 2024: $7,689 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,175 · Education: $4,089 · Travel and Lodging: $2,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,174.96 |
| Education | $4,088.64 |
| Travel and Lodging | $2,560.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,648.34 | 2023-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,310.56 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,072.43 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $635.26 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.46 | 2019-2025 | Ofev, Spiriva Respimat |
| Grifols USA, LLC | $552.31 | 2019-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $431.62 | 2019-2020 | |
| United Therapeutics Corporation | $393.12 | 2020-2025 | Tyvaso, Orenitram, Remodulin |
| Takeda Pharmaceuticals U.S.A., INC. | $311.46 | 2020-2025 | Glassia |
| Genzyme Corporation | $239.10 | 2021-2025 | |
| Baxter Healthcare | $227.68 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Actelion Pharmaceuticals US, INC. | $213.21 | 2019-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $188.23 | 2019-2023 | Yupelri |
| Mallinckrodt Hospital Products INC. | $149.59 | 2020-2022 | |
| Insmed, INC. | $128.07 | 2024-2025 | Arikayce |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $114.15 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Verona Pharma, INC. | $112.79 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $111.73 | 2019 | |
| Advanced Respiratory, INC | $68.04 | 2019-2021 | |
| Vifor Pharma, INC. | $66.20 | 2019-2020 | |
| Viatris Specialty LLC | $59.50 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $57.59 | 2019-2024 | |
| Olympus America INC. | $56.77 | 2023-2025 | Single-Use Flexible Video Bronchoscope |
| Inspire Medical Systems, INC. | $52.00 | 2023 | Inspire |
| Mallinckrodt Enterprises LLC | $51.59 | 2019 | |
| Pulmonx Corporation | $50.14 | 2022-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Fujifilm Healthcare Americas Corporation | $40.25 | 2024 | Fujifilm |
| Boston Scientific Corporation | $38.13 | 2025 | Cds - Mct/Cem Monitoring |
| Electromed, INC. | $33.57 | 2025 | Smartvest |
| Harmony Biosciences LLC | $25.99 | 2021 | |
| Genentech USA, INC. | $25.46 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.90 | 2025 | Purified Cortrophin Gel |
| Resmed Corp | $22.50 | 2025 | |
| Medtronic, INC. | $18.79 | 2025 | Illumisite |
| Amgen INC. | $18.62 | 2024 | Tezspire |
| Shire North American Group INC | $17.96 | 2019 | |
| 3b Medical, INC. | $17.08 | 2023 | Luna |
| Alexion Pharmaceuticals, INC. | $16.82 | 2019 | |
| Merck Sharp & Dohme LLC | $16.67 | 2023 | |
| Gilead Sciences, INC. | $16.53 | 2022 | |
| Liquidia Technologies, INC. | $14.50 | 2025 | Yutrepia |
| Ceribell, INC. | $13.92 | 2023 | Ceribell Rapid Response |
| Chiesi USA, INC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Malte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.